PHILADELPHIA — Lawyers spent 12 hours last week interviewing expert witnesses in a hearing for a large lawsuit against the makers of drugs including Ozempic and Mounjaro. How federal Judge Karen Marston interprets their testimony may change the course of the litigation, which includes nearly 2,000 plaintiffs from across the country.
A trial date has not been set for the case, which names drug makers Eli Lily and Novo Nordisk as defendants. The multidistrict litigation is assigned to federal court in Philadelphia because of its proximity to Novo Nordisk headquarters in Plainfield, N.J., according to CBS News.
The hearing on Wednesday came as the lawsuit grows, with the number of plaintiffs increasing every day, according to plaintiff attorney Jonathan Orent — and as the medications are more popular than ever.
The day in U.S. District Court of Eastern Pennsylvania was spent deliberating over specifics, in ardent detail, of the gastrointestinal condition gastroparesis, and a main way doctors diagnose it: with a costly scan known as a gastric emptying test.
This is key to the case and how it might proceed, as 83% of the plaintiffs allege gastroparesis-related harm from the drugs, according to Mr. Orent. But 40% of them have not had the gastric test. If Judge Marston decides that scan is required as evidence of injury, hundreds of plaintiffs could be deemed ineligible.
And the three expert witnesses disagreed, both on whether the test was crucial and what constitutes true gastroparesis.
Read More
Also important to their arguments, and debated repeatedly, was whether a patient on a GLP-1 — the class of medications that Ozempic belongs to, also known as glucagon-like-peptides — can safely be given a gastric emptying test. Lawyers brought up guidelines that suggested doing so would skew results of the test, while one witness said it’s safe to do so.
Gastroparesis, characterized by damage to the nerves that control stomach muscles, causing delayed gastric emptying, is considered to be rare, and it’s often mistaken for functional dyspepsia, or chronic indigestion. Gastroparesis is more common in women and people with diabetes, an infection or who recently had surgery.
The test, which takes up to four hours, asks patients to consume a meal of scrambled eggs with a radioactive tracer, toast and jam so doctors can watch the food moving through the digestive tract using a series of X-rays. This helps give evidence of whether that process is delayed.
While symptoms that align with gastroparesis can be drug-induced, there are fewer guidelines for diagnosing and treating a medication-induced case versus one occurring from another cause, muddying the waters of the testimony on Wednesday and leaving the expert witnesses at odds.
The defense believes the gastric emptying test is not only helpful, but also required by most guidelines to accurately assess objective proof of gastroparesis.
There are challenges to receiving the test, which can cost up to $2,000. The test may not be available for weeks, and pregnant people, those with allergies to the standard meal, and those taking GLP-1s or on other medications like the diabetes drug metformin are not eligible for it.
“I think the evidence is pretty clear that the medical practitioners across this country who utilize a differential diagnosis process to diagnose medically drug-induced gastroparesis, particularly with GLP-1s, are on solid footing,” said Mr. Orent.
Differential diagnosis refers to a process in which physicians gather all the information they can on a patient and propose multiple possible diagnoses for their condition. It’s a term that came up repeatedly during the hearing as a process physicians can use to decide whether a patient has gastroparesis. It may include an array of imaging tests in addition to a gastric emptying study.
To properly diagnose gastroparesis, doctors must have objective evidence of delayed gastric emptying, presence of patient symptoms and a lack of mechanical obstruction in the gut that may otherwise be preventing food from moving through. These three conditions must be met in order for a diagnosis to be reached.
The American College of Gastroenterology 2022 guidelines state a gastric emptying test is required to diagnose the condition, but do not specifically address drug-induced gastroparesis.
Dr. Daniel Raines, a professor of gastroenterology at Louisiana State University, was questioned on the stand for more than four hours. He repeatedly argued that patients with drug-induced gastroparesis are considered atypical and distinct from patients with other types of gastroparesis or symptoms of delayed gastric emptying not from drugs.
Dr. Raines said he diagnoses many people with drug-induced gastroparesis without ordering a gastric emptying test, because other tests, such as CT scans and upper endoscopies, provide viable proof for the condition.
He described a patient who had been taking semaglutide for diabetes who came to him with complaints of vomiting. Semaglutide is FDA-approved under the name Ozempic for diabetes and as Wegovy for weight management; both are Novo Nordisk medications.
“He said he had a roast beef sandwich and a bag of cookies seven hours before,” explained Dr. Raines. “The scan showed a bunch of food in his stomach.” With even big meals passing out of the stomach in four hours, this to him was clear evidence of delayed gastric emptying, further confirmed by two imaging tests.
“A gastric emptying test is an ideal way to diagnose gastroparesis, but it’s not the only way,” he asserted.
Dr. Raines may change the diagnosis if a patient’s symptoms improve dramatically or their symptoms reveal to be indicative of a different condition. To him, this was the normal process of differential diagnosis in medicine.
But to Dr. Linda Anh Nguyen, symptoms that resolve when a patient stops taking a drug must not be true gastroparesis.
The professor of medicine and interim chief of Stanford University’s Division of Gastroenterology and Hepatology said she would never diagnose someone with gastroparesis without a gastric emptying test, and that true gastroparesis is a lifelong and incurable condition.
“Nausea, vomiting and early satiety can be involved in many other conditions including functional dyspepsia,” she said on the stand. “Symptoms alone cannot differentiate between these conditions. You need the gastric emptying study to confirm these symptoms are indeed related to gastroparesis and not other mechanisms.
“Only after a gastric emptying test will I tell patients they definitively have gastroparesis,” she said. “That’s when I make the diagnosis.”
She didn’t necessarily agree with the term “drug-induced gastroparesis”: While she uses it, she said she thinks “drug-induced delayed gastric emptying” is more accurate.
Plaintiff lawyers took issue with the fact that Dr. Nguyen had been a paid consultant for Eli Lilly prior to being paid to be an expert witness for the defense. On the stand, she asserted that her consultation involved migraine medication and therefore was not relevant to the lawsuit. Dr. Nguyen also helped write the 2022 American College of Gastroenterology guidelines.
"Lilly is continuously innovating and researching new potential treatment options. Years before this MDL was formed, Dr. Nguyen used her well-recognized medical expertise in gastric motility to help design a clinical trial investigating a potential migraine treatment,” said an Eli Lilly spokesperson in an emailed statement Friday.
Dr. Eliot Siegel, the third expert witness and a nuclear medicine physician and radiologist who has conducted about 2,000 gastric emptying tests, said the test “absolutely cannot” alone confirm whether a patient has gastroparesis.
Dr. Siegel is former chief of diagnostic radiology and nuclear medicine at the VA Maryland Healthcare system in Baltimore and a tenured professor and vice chair in the department of radiology at the University of Maryland School of Medicine.
Overall, the hours of testimony seemed to be a difference in practicing preference than a crucial deviation away from any guidelines.
On Monday, lawyers for both sides will present their closing arguments. It could take months for Judge Marston to rule on the issue.
“I imagine it will take some time, but I honestly don’t know what’s next,” said Mr. Orent. “Plaintiffs are constantly bringing their cases, and gastroparesis is only one of multiple injuries. Each of these people is looking forward to their day in court.”






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.